NUVAXOVIDᵀᴹ dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) For Individuals 12 Years and Older - Switzerland - European Medical Journal

Continue

NUVAXOVIDᵀᴹ dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) For Individuals 12 Years and Older – Switzerland

Respiratory
Microbiology & Infectious Diseases

COVID-19 Vaccine update: learn about the clinical efficacy and safety data for a new recombinant protein subunit COVID-19 vaccine approved and available in >35 countries. The video can be viewed at your convenience.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given